Table 4.
Characteristics of observational studies included
| Study | Design | Exposure | pop. (n) | Mean eGFR (mL.min) | Age(y) mean Total | Mean Hb mg.dl (sd) | ESA use (%) | Diabetes (%) | Follow up (months) | Instrument | Population characteristics | Estimates for mean difference PCS | Estimates for mean difference fatigue | Quality score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plantinga, L. | Prospective Cohort | Hb > 11 after 6 months starting HD | 438 | 5D | 60 | 10.4 | 70% | NR | 12 | SF-36 | Incident HD patients, > 18 years, HRQOL collected | 1.56 (0.16,2.96) | 2.39 (-0.51,5.29) | 8 |
| Freburger | Retrospective Cohort | ESA dose terciles and Iron treatment | 13,039 | 5D | 59 | 11.8 | 94% | 60% (42%) | 12 | SF-36 | Prevalent HD pts., Medicare database, TSAT + HRQOL | Overall: - 0.1 (-0.7 to 0.5). Hb < 11 g/dL: 2.5 (0.6 to 4.3) | NR | 6 |
| De Goeij | Prospective Cohort | 11 < Hb < 12 vs. Hb > 13 | 371 | 16.9 | 69 (55–76) | 12.3 (1.5) | 48 | 26 (13) | 24 | SF-36 | Prevalent pre-dialysis patients | Overall: 4.9 * - younger/ESA 8.9 (2.1, 15.8) | 5 * | 8 |
| Binder | Prospective Cohort | Anemia (WHO criteria) | 311 | 45 | 84 | 12 | 0 | 42 | 26 | Barthel index | Nursing residents with CKD | – | – | 5 |
| Schnelle | Retrospective Cohort | Anemia (WHO criteria) | 173 | 40 | 84 (7) | NR | NR | NR | 12 | NR | Nursing residents with CKD | – | – | 2 |
HD Hemodialysis, TSAT Transferrin Saturation, WHO World Health Organization (Hb < 12 g/dL). * Confidence interval not provided. P value reported as significative. PCS Physical Component Score, DM Diabetes mellitus, Mo Months, CHD Coronary heart disease. IHD Ischemic Heart Disease, M Male, LV Left Ventricular, RRT Renal replacement therapy, NR Not reported, 5D Stage 5 CKD, IV Intravenous